Euclidean Capital’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-992,168
| Closed | -$1.58M | – | 13 |
|
|
2024
Q1 | $1.58M | Hold |
992,168
| – | – | 0.2% | 11 |
|
|
2023
Q4 | $852K | Hold |
992,168
| – | – | 0.1% | 11 |
|
|
2023
Q3 | $1.06M | Buy |
992,168
+245,494
| +33% | +$263K | 0.23% | 11 |
|
|
2023
Q2 | $1.93M | Hold |
746,674
| – | – | 0.5% | 11 |
|
|
2023
Q1 | $3.05M | Hold |
746,674
| – | – | 2.67% | 8 |
|
|
2022
Q4 | $3.75M | Hold |
746,674
| – | – | 3.51% | 9 |
|
|
2022
Q3 | $9.77M | Hold |
746,674
| – | – | 9.07% | 5 |
|
|
2022
Q2 | $9.57M | Hold |
746,674
| – | – | 8.14% | 5 |
|
|
2022
Q1 | $11.4M | Hold |
746,674
| – | – | 6.62% | 5 |
|
|
2021
Q4 | $13.2M | Sell |
746,674
-85,600
| -10% | -$1.52M | 7.52% | 6 |
|
|
2021
Q3 | $17.5M | Sell |
832,274
-661,075
| -44% | -$13.9M | 8.5% | 6 |
|
|
2021
Q2 | $29.4M | Hold |
1,493,349
| – | – | 9.56% | 2 |
|
|
2021
Q1 | $43.4M | Sell |
1,493,349
-590,253
| -28% | -$17.2M | 14.53% | 2 |
|
|
2020
Q4 | $63.1M | Buy |
+2,083,602
| New | +$63.1M | 13.37% | 2 |
|